CONFIDENTIAL DATA RELEASED TO SUMMIT INCLUDED WIDE RANGE OF INFORMATION, NOT LIMITED TO VISX; TYPE OF DATA RELEASED SHOWS NO OBVIOUS MOTIVE, FDAers SAY
This article was originally published in The Gray Sheet
Executive Summary
The package of confidential FDA documents released to Summit Technology in late November 1995 contained a wide range of information, including data on Summit's main competitor Visx, ophthalmic surgeon Fred Kremer, MD, and potentially other individuals or companies.
You may also be interested in...
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.
MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation
Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.
Incyte Hopes To Augment Immune/Inflammation Pipeline With Escient Deal
Incyte will pay $750m to acquire privately held Escient and its first-in-class oral antagonists of Mas-related G protein-coupled receptors X2 and X4.